On Thursday, UBS adjusted its stance on CVS Health (NYSE:CVS), moving its stock rating from Buy to Neutral. Additionally, the firm has revised its price target for CVS shares downwards to $60.00, a significant decrease from the previous target of $85.00.
This decision stems from concerns about the company's ability to make necessary improvements in its Medicare Advantage (MA) cost trend and other business segments that are critical to meeting current guidance expectations.
The downgrade follows CVS Health's release of a softer-than-expected first-quarter earnings per share (EPS) of $1.31. According to UBS, this performance has introduced a wider range of possible outcomes for the company's aim to reach $7 in EPS for the full year. Analysts at UBS have acknowledged CVS management's detailed explanation of the assumptions behind the new EPS and medical loss ratio (MLR) guidance, as well as their conservative outlook for the Health Services (HSS) and Health Care Benefits (HCB) segments.
UBS has expressed concerns that achieving low double-digit EPS growth in 2025 may increasingly rely on CVS Health's capital deployment strategies. However, this may be challenged by management's intention to maintain an investment-grade credit rating. Furthermore, the potential $700 million Stars bonus payment, which is contingent on the company's current MA membership level, may also be at risk if the plans experience higher than anticipated churn rates.
InvestingPro Insights
As CVS Health (NYSE:CVS) navigates the challenges highlighted by UBS, real-time metrics from InvestingPro paint a broader picture of the company's financial health. With a market capitalization of $70.69 billion and a P/E ratio standing at 11.86, CVS shows signs of a valuation that may attract investors looking for potentially undervalued opportunities. The company's revenue growth has been positive over the last twelve months as of Q1 2024, with a 9.02% increase, suggesting operational expansion despite current headwinds.
InvestingPro Tips indicate that CVS's stock is currently in oversold territory according to the RSI, and it is trading at a low revenue valuation multiple. These factors, combined with CVS's strong free cash flow yield, may interest investors seeking companies with robust cash-generating capabilities. Moreover, CVS has maintained dividend payments for 54 consecutive years, with a dividend yield of 4.72% as of the latest data, which may appeal to income-focused investors. For those considering a deeper dive into CVS Health's investment potential, InvestingPro offers additional insights, including 13 more InvestingPro Tips for CVS, available at: https://www.investing.com/pro/CVS. Readers can use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.